U.S. drugmaker Merck said on Thursday its experimental combination treatment for some adults with HIV-1 infection met the ...

This issue highlights a broader concern regarding medication coverage and affordable health care. It underscores the critical ...

Biotech giant Gilead Sciences, Inc. GILD has put up a steady performance in 2024 amid a volatile market. Its shares have ...

ICER's 2023 report highlights five drugs with unsupported price increases, leading to $815 million in excess costs for U.S.

The drug for which spending increased the most due to a price increase was Gilead’s HIV treatment Biktarvy. The company ...

The change would have applied to common HIV medications like Biktarvy, a once-daily pill. The provider will also cover all eight nationally recommended treatment regimens for HIV, the bureau said in a ...

However, the combination of Merck's approved doravirine and investigational islatravir didn't prove superiority over Gilead's ...

GSK has fired a shot across the bows of Gilead Sciences' HIV juggernaut Biktarvy, with new data showing its rival therapy Dovato is as effective but causes less weight gain. The results of the ...

Gilead Sciences, Inc. (NASDAQ:GILD), a biopharmaceutical company, discovers, develops and commercializes medicines to address ...

Investors are bullish on Gilead as the stock surges on successful launches and strong financial health, offering potential ...

For years, Gilead Sciences was dead money for shareholders. Shares of the drugmaker, with a market capitalization of just ...

The Maine Bureau of Insurance announced Monday that the carrier reversed its initial decision and will cover eight HIV ...